

# The NCRI adjuvant breast cancer (ABC) trial

<b>Submission date</b> 06/04/2000	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/04/2000	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/05/2013	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Study website

[http://www.icr.ac.uk/research/research\\_sections/clinical\\_trials/clinical\\_trials\\_list/2413\\_disease.shtml](http://www.icr.ac.uk/research/research_sections/clinical_trials/clinical_trials_list/2413_disease.shtml)

## Contact information

### Type(s)

Scientific

### Contact name

Ms Judith Bliss

### Contact details

Section of Epidemiology  
The Institute of Cancer Research  
15 Cotswold Road  
Sutton  
United Kingdom  
SM2 5NG  
+44 (0)20 8722 4040  
[abc-icrctsu@icr.ac.uk](mailto:abc-icrctsu@icr.ac.uk)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00002582

## Secondary identifying numbers

G9437812

# Study information

## Scientific Title

## Acronym

ABC

## Study objectives

To determine the value of adding cytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression to prolonged tamoxifen in women with early breast cancer.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Breast cancer

## Interventions

Cytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression and prolonged tamoxifen/tamoxifen

## Intervention Type

Other

**Phase**

Not Specified

**Primary outcome measure**

The main endpoint used for evaluation of treatment efficacy will be overall survival based on all cause mortality. Relapse-free survival, breast cancer mortality and cardiovascular mortality will also be compared. In a subset of patients there will be a detailed assessment of quality of life. Health economic consequences will also be determined. Ongoing biological predictors of therapeutic response studies, funded by CRUK and BCC.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/1993

**Completion date**

30/09/2005

**Eligibility****Key inclusion criteria**

All women with early invasive breast cancer requiring adjuvant systemic therapy are eligible for the trial providing they have:

1. Early (operable) breast cancer
2. Histological confirmation of invasive carcinoma
3. No previous malignancy (except carcinoma in situ [CIS] cervix or basal cell carcinoma)
4. Received no previous systemic treatment for their disease
5. Given consent and available for subsequent follow-up

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

6000

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1993

**Date of final enrolment**

30/09/2005

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

### Section of Epidemiology

Sutton

United Kingdom

SM2 5NG

# Sponsor information

## Organisation

Institute of Cancer Research (UK)

## Sponsor details

123 Old Brompton Road

London

United Kingdom

SW7 3RP

+44 (0)20 7352 8133

abc-icrctsu@icr.ac.uk

## Sponsor type

Research organisation

## Website

<http://www.icr.ac.uk/>

## ROR

<https://ror.org/043jzw605>

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (UK)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	04/04/2007		Yes	No
<a href="#">Results article</a>	results	14/03/2012		Yes	No